| 000 | 01391 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250517081908.0 | ||
| 264 | 0 | _c20170303 | |
| 008 | 201703s 0 0 eng d | ||
| 022 | _a1607-8454 | ||
| 024 | 7 |
_a10.1080/10245332.2015.1122259 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhou, Xin | |
| 245 | 0 | 0 |
_aReal-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience. _h[electronic resource] |
| 260 |
_bHematology (Amsterdam, Netherlands) _cJun 2016 |
||
| 300 |
_a280-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAsian People |
| 650 | 0 | 4 |
_aBortezomib _xadministration & dosage |
| 650 | 0 | 4 | _aChina |
| 650 | 0 | 4 | _aCosts and Cost Analysis |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Myeloma _xdrug therapy |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aXia, Jun | |
| 700 | 1 | _aMao, Jingjue | |
| 700 | 1 | _aCheng, Feng | |
| 700 | 1 | _aQian, Xifeng | |
| 700 | 1 | _aGuo, Hongfeng | |
| 773 | 0 |
_tHematology (Amsterdam, Netherlands) _gvol. 21 _gno. 5 _gp. 280-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/10245332.2015.1122259 _zAvailable from publisher's website |
| 999 |
_c25755797 _d25755797 |
||